Overview

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety of UCB4940 administered by iv infusion of a single ascending dose in subjects with mild to moderate plaque psoriasis.

Phase:

Phase 1

Details

Lead Sponsor:

UCB Celltech